Therapix Biosciences Ltd. (NASDAQ:TRPX) Issues Quarterly Earnings Results
Therapix Biosciences Ltd. (NASDAQ:TRPX) released its quarterly earnings results on Thursday. The company reported ($0.54) EPS for the quarter, Morningstar.com reports.
Shares of Therapix Biosciences (NASDAQ TRPX) traded down 4.16% during trading on Thursday, reaching $5.30. 27,571 shares of the company’s stock were exchanged. Therapix Biosciences has a 52 week low of $5.21 and a 52 week high of $13.19. The stock has a 50 day moving average price of $6.87 and a 200-day moving average price of $7.09. The stock’s market capitalization is $18.33 million.
ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/10/therapix-biosciences-ltd-nasdaqtrpx-issues-quarterly-earnings-results.html.
Separately, Ladenburg Thalmann Financial Services lowered shares of Therapix Biosciences to a “buy” rating in a research report on Monday, June 5th.
About Therapix Biosciences
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.
Receive News & Ratings for Therapix Biosciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Therapix Biosciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.